论文部分内容阅读
目的 :研究急性心肌梗死后患者口服华法林的疗效及安全性。方法 :10 0例急性心肌梗死住院患者 ,随机分成 2组。华法林组服用华法林 3mg/d开始 ,根据国际标准化比值 (INR)调整华法林剂量 ,维持INR2 .0～ 3.0 ;阿司匹林组口服肠溶阿司匹林 10 0mg/d。 2组均随访 1a。结果 :华法林组新发心肌梗死发生率、不稳定性心绞痛发生率 ,心血管病因再住院率、心血管病因死亡率均低于肠溶阿司匹林组 (P <0 .0 5 ) ;华法林组总出血率高于肠溶阿司匹林组 (P <0 .0 5 ) ,但大多为能够耐受的小出血 ,不影响治疗。结论 :心肌梗死患者长期服用华法林安全有效
Objective: To study the efficacy and safety of oral warfarin in patients with acute myocardial infarction. Methods: One hundred and ten hospitalized patients with acute myocardial infarction were randomly divided into two groups. Warfarin group started with warfarin 3mg / d, according to the international standardization ratio (INR) adjusted warfarin dose, maintain INR2 .0 ~ 3.0; aspirin group oral enteric-coated aspirin 10mg / d. Both groups were followed for 1a. Results: The incidence of new myocardial infarction, unstable angina, cardiovascular rehospitalization and cardiovascular mortality in warfarin group were lower than those in enteric-coated aspirin group (P0.05) The total hemorrhage rate in forest group was higher than that in enteric-coated aspirin group (P <0.05), but most of them were able to tolerate small hemorrhage without affecting the treatment. Conclusions: Long-term use of warfarin in patients with myocardial infarction is safe and effective